ClinicalTrials.gg

Program

Vaccines, Combined

Also written as “Hexavalent (DTwP-HepB-rPV-Hib) Vaccine”, “LBVD (Hexavalent vaccine)” and “DPT-IPV-Hib (Combined Vaccine)”.

Its studies are mostly in Hepatitis B · Diphtheria · Haemophilus Infections · Tetanus, led by 3 companies.

Furthest: phase 3, since Jun 13, 20174 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tanabe Pharma20 open or runningphase 3since Jun 13, 2017Jun 13, 2017none ahead
LG Chem10 open or runningphase 3since Jul 11, 2022Jul 11, 2022none ahead
Serum Institute of India Pvt.11 open or runningphase 2since Sep 21, 2026Sep 21, 2026Oct 2027phase 2 · NCT07855172

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 13, 2017First study: phase 3 study in Haemophilus InfectionsNew to Tanabe PharmaTanabe Pharma · NCT03188692 · 33 enrolled · Japan
  2. Mar 24, 2019Phase 3 study in TetanusTanabe Pharma · NCT03891758 · 267 enrolled · Japan
  3. Jul 11, 2022LG Chem's first study: phase 3 study in DiphtheriaNew to LG ChemLG Chem · NCT05457946 · 60 enrolled · South Korea
  4. Sep 21, 2026Serum Institute of India Pvt.'s first study: phase 2 study in Diptheria ImmunizationNew to Serum Institute of India Pvt.Serum Institute of India Pvt. · NCT07855172 · 186 planned · Bangladesh

Ahead

  1. Oct 2027Primary completion: phase 2 study in Diptheria ImmunizationSerum Institute of India Pvt. · NCT07855172

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07855172Diptheria Immunization · Bangladesh2RecruitingSerum Institute of India Pvt.Oct 2027186
NCT05457946Diphtheria · South Korea3CompletedLG ChemFeb 21, 201960
NCT03891758Tetanus · Japan3CompletedTanabe PharmaSep 18, 2019267
NCT03188692Haemophilus Infections · Japan3CompletedTanabe PharmaNov 2, 201733

How it is read

Names in the registry

  • “Hexavalent (DTwP-HepB-rPV-Hib) Vaccine”, 1 entry
  • “LBVD (Hexavalent vaccine)”, 1 entry
  • “DPT-IPV-Hib (Combined Vaccine)”, 1 entry
  • “DPT-IPV-Hib”, 1 entry

Codes read as this program: BK1310.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.